Drugs / Tecemotide
Tecemotide
also known as
L-BLP25 · Blp-25 lipopeptide · BLP25 · BP-1-148 · EMD 531444 · Emepepimut-s · LIPOPEPTIDE BLP-25 · Stimuvax · +1 more
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01731587 | Jan 2001 → ? | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00960115 | Dec 2008 → May 2014 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT01507103 | Feb 2012 → Jun 2014 | rectal cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01496131 | Oct 2011 → Nov 2016 | prostate cancer | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT01462513 | Aug 2011 → Dec 2017 | colon carcinoma, rectal carcinoma | Prof. Dr. Carl Schimanski | Completed | No outcome recorded |
| Phase 2 | NCT00828009 | Jan 2011 → Aug 2018 | lung cancer | ECOG-ACRIN Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT01094548 | Jan 2008 → Feb 2011 | plasma cell myeloma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00157196 | Apr 2005 → Sep 2007 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00157209 | Aug 2000 → Mar 2006 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02049151 | Mar 2014 → Jul 2015 | non-small cell lung carcinoma | EMD Serono | Terminated | No outcome recorded |
| Phase 3 | NCT01015443 | Dec 2009 → Jun 2015 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 3 | NCT00925548 | Sep 2009 → Aug 2010 | breast cancer | EMD Serono | Terminated | No outcome recorded |
| Phase 3 | NCT00409188 | Jan 2007 → Apr 2012 | non-small cell lung carcinoma | EMD Serono | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01423760 | Jan 2012 → Jul 2015 | non-small cell lung carcinoma, plasma cell myeloma | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tecemotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00409188 ↗ |
| Known as | Blp-25 lipopeptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Known as | BLP25 | “BLP25 liposome vaccine (tecemotide)” NCT00828009 ↗ |
| Known as | BP-1-148 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Known as | EMD 531444 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Known as | Emepepimut-s | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Known as | L-BLP25 | “Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals,...” NCT01731587 ↗7“After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at...” NCT00157209 ↗ “The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective” NCT00409188 ↗ “Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination.” NCT01094548 ↗ “Common Safety Follow-up Trial of Tecemotide (L-BLP25)” NCT01423760 ↗ “Tecemotide (L-BLP25)” NCT01507103 ↗ “Tecemotide (L-BLP25)” NCT00157196 ↗ |
| Known as | LIPOPEPTIDE BLP-25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Known as | Stimuvax | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Known as | Tecemotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039544 ↗ |
| Action | Deplete | “designed to induce an immune response resulting in elimination of tumor cells expressing the MUC1 antigen” PMID 21071331 ↗ Nov 2010 |
| Modality | Vaccine | “the cancer vaccine tecemotide (L-BLP25)” NCT00409188 ↗ |
| Route | Subcutaneous | “8 consecutive weekly subcutaneous vaccinations” NCT00157196 ↗ |
| Target | MUC1 | “experimental mucinous glycoprotein 1 (MUC1) antigen-specific cancer immunotherapy” NCT00925548 ↗ |